OncoMatch/Clinical Trials/NCT05544019
Study of SGR-1505 in Mature B-Cell Neoplasms
Is NCT05544019 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies SGR-1505 for mature b-cell neoplasm.
Treatment: SGR-1505 — The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner Health - MD Anderson Cancer Center · Gilbert, Arizona
- Christiana Care Hospital - Helen F Graham Cancer Center · Newark, Delaware
- Napa Research · Pompano Beach, Florida
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Regional Cancer Care Associates · Hackensack, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05544019 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify